Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03237611 · ClinicalTrials.gov registry record · Phase 2
Low Dose Aprepitant for Patients Receiving Carboplatin
A Phase 2 study, sponsored by Albert Einstein College of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT03237611 is a Phase 2 study that was terminated before completion, run by Albert Einstein College of Medicine. The registered enrollment target is 15 participants.
The verdict
NCT03237611, a Phase 2 study, was terminated before completion, sponsored by Albert Einstein College of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study evaluates a simple one day prophylaxis of nausea and vomiting for patients who are getting carboplatin based chemotherapy. In addition to standard oral Dexamethasone and oral Ondansetron, participants will be given a third neurokinin 1 (NK1) antagonist agent, either a single dose of oral Aprepitant or intravenous (IV) Fosaprepitant (they have been shown to be equally effective) to improve prevention of nausea and vomiting. No medications need to be taken beyond day 1.
Interventions
- DRUG Dexamethasone
- DRUG Aprepitant 125 mg
- DRUG Fosaprepitant 115 MG
- DRUG Ondansetron 16 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2018-10-30 |
| Est. Completion | 2021-02-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03237611
The ClinicalTrials.gov registry entry for NCT03237611 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dexamethasone is the first listed.
NCT03237611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03237611 about?
NCT03237611 is a clinical study titled "Low Dose Aprepitant for Patients Receiving Carboplatin". This study evaluates a simple one day prophylaxis of nausea and vomiting for patients who are getting carboplatin based chemotherapy. In addition to standard oral Dexamethasone and oral Ondansetron, participants will be given a third neurokinin 1 (NK1) antagonist agent, either a single dose of oral ...
What is the current status of trial NCT03237611?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2018-10-30. Estimated completion is 2021-02-11.
What interventions are being tested in trial NCT03237611?
The interventions under investigation include: Dexamethasone (DRUG), Aprepitant 125 mg (DRUG), Fosaprepitant 115 MG (DRUG), Ondansetron 16 MG (DRUG).
Who is sponsoring clinical trial NCT03237611?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.